The bill directs the Secretary of Veterans Affairs to run a three-year pilot program that furnishes hyperbaric oxygen therapy (HBOT) to veterans diagnosed with traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD). The pilot must operate in two Veterans Integrated Service Networks (VISNs), restrict care to accredited facilities, and define HBOT as treatment delivered by devices either approved by the FDA or operating under an FDA investigational device exemption.
Funding for treatment under the pilot comes exclusively from a new donor-funded account, the "VA HBOT Fund," managed by the Secretary and available without fiscal year limitation.
The measure also mandates a GAO update to the 2016 report on HBOT clinical evidence and amends 38 U.S.C. 5503(d)(7) to extend an existing limit on pension payments until October 30, 2034. For providers, VA leaders, and veteran advocates, the bill creates a time-limited, geographically narrow effort to expand access to a controversial therapy while leaving key operational choices—eligibility rules, enrollment caps, and how donations are solicited—to VA implementation.
At a Glance
What It Does
The bill requires the VA to implement a three-year pilot that provides HBOT to veterans with TBI or PTSD through providers authorized under 38 U.S.C. §1703(c)(5). Facilities administering HBOT must hold accreditation from the Joint Commission, the Undersea and Hyperbaric Medical Society, or an equivalent body; devices must be FDA-approved or have an investigational device exemption.
Who It Affects
Directly affects veterans with TBI or PTSD seeking HBOT, VA medical centers and the two VISNs chosen to operate the pilot, and accredited hyperbaric facilities that may contract with VA. It also implicates VA program managers who must administer a donor-funded account and report to Congress via GAO.
Why It Matters
This creates a donor-funded pathway for veterans to receive a therapy where the evidence base remains contested, concentrates implementation and data collection in two VISNs, and forces a short-term evaluation window. The funding structure avoids appropriations, which both limits scale and raises questions about sustainability and equity of access.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill instructs the VA to stand up a limited pilot to provide hyperbaric oxygen therapy to veterans diagnosed with traumatic brain injury or post-traumatic stress disorder. VA must operate the pilot inside two Veterans Integrated Service Networks, but the law does not prescribe which VISNs or the clinical eligibility criteria; those implementation details fall to the Secretary.
The pilot is expressly routed through health-care providers described in 38 U.S.C. §1703(c)(5), meaning care will be furnished through VA-authorized non-VA provider arrangements rather than as a blanket entitlement at all VA facilities.
To participate, a medical facility must be accredited by either the Joint Commission, the Undersea and Hyperbaric Medical Society, or an organization judged by the VA to have comparable expertise and objectivity. The bill defines the therapy in regulatory terms: HBOT treatments must be delivered with a device that is either FDA-approved or operating under an FDA investigational device exemption.
That dual definition allows use of cleared commercial devices and, under controlled conditions, investigational devices still in trial.Funding for covered HBOT services under the pilot cannot come from regular appropriations; instead the statute creates a dedicated "VA HBOT Fund" seeded and replenished only by donations earmarked for the Fund. The law makes Fund balances available to the VA without fiscal-year limitations, but it ties the Fund’s lifespan to the pilot: both the Fund and the pilot expire three years after enactment.
The Secretary therefore gains authority to pay for care from donated monies but receives no new, permanent appropriations to scale the program beyond the pilot timeframe.Separately, the bill requires the Government Accountability Office to update its 2016 review of HBOT evidence within one year, explicitly assessing clinical trials conducted since that report by the VA, Department of Defense, and private entities. Finally, the bill amends 38 U.S.C. §5503(d)(7) to push the sunset of a current pension-payment limitation to October 30, 2034, an unrelated adjustment that affects veterans’ pension administration timelines.
The Five Things You Need to Know
The pilot is limited to two Veterans Integrated Service Networks and terminates three years after the date of enactment.
The statute establishes a "VA HBOT Fund" whose sole source of money is donations; VA may spend Fund balances without fiscal-year limitation but the Fund dissolves when the pilot ends.
Participating treatment sites must be accredited by the Joint Commission, the Undersea and Hyperbaric Medical Society, or an organization found comparable by VA.
HBOT is defined to include treatments delivered with devices that are FDA-approved or operating under an FDA investigational device exemption (IDE).
The GAO must submit, within one year, an update to GAO-16-154 assessing clinical trials since that report carried out by VA, DOD, and private entities; the bill also extends the date in 38 U.S.C. §5503(d)(7) to October 30, 2034.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short name: the "Veterans National Traumatic Brain Injury Treatment Act." This section has no operational effect beyond labeling the statute for reference.
Pilot program to furnish HBOT to veterans with TBI or PTSD
Subsection (a) directs the Secretary of Veterans Affairs to implement a pilot that furnishes hyperbaric oxygen therapy to veterans who have traumatic brain injury or post‑traumatic stress disorder, and specifies that care must be delivered through providers described in 38 U.S.C. §1703(c)(5). Subsection (b) limits operation to two VISNs, concentrating treatment and evaluation in a narrow geographic sample. Subsection (c) requires facility accreditation (Joint Commission, Undersea and Hyperbaric Medical Society, or a comparable accreditation body), placing a gate on which clinics may participate and allowing VA to use accreditation as a quality-control lever. Subsection (d) creates the VA HBOT Fund, funded only by donations and available without fiscal-year limits, which means the program has a non‑appropriated funding source but also depends on philanthropic inflows. Subsection (e) sets a three-year statutory sunset for the pilot and the Fund. Subsection (f) defines HBOT in regulatory terms to permit both FDA-cleared devices and devices covered by investigational device exemptions.
GAO update of HBOT evidence
Mandates that the Comptroller General submit, within one year, an update to the GAO-16-154 report. The update must assess clinical trials conducted since the original GAO review by three actor groups: the VA, the Department of Defense, and private entities. The language signals congressional interest in an evidence synthesis that explicitly includes VA- and military‑sponsored trials, potentially shaping whether the VA broadens or ends the therapy after the pilot.
Extension of pension-payment limit date
Amends 38 U.S.C. §5503(d)(7) by replacing the termination date 'November 30, 2031' with 'October 30, 2034.' That change extends the existing statutory limit referenced by 5503(d)(7) by nearly three years. The amendment is administrative in form—adjusting an expiration date rather than altering benefits formulas—but it affects the timeframe for pension payment limits that administrators must follow.
This bill is one of many.
Codify tracks hundreds of bills on Veterans across all five countries.
Explore Veterans in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with TBI or PTSD seeking HBOT: The pilot creates a funded pathway for eligible veterans in the chosen VISNs to receive HBOT without waiting for a change to VA-wide policy.
- Accredited hyperbaric facilities: Centers that already meet Joint Commission or UHMS standards may win contracts or referral volume from VA-authorized care within the pilot VISNs.
- Clinical researchers and VA research programs: Concentrated, VA‑run treatment cohorts provide an opportunity to collect standardized outcome data and add to the evidence base if VA links clinical care with rigorous evaluation.
- Veteran advocacy organizations: Groups advocating for expanded therapeutic options gain a targeted program they can point to as access that was previously unavailable within VA benefits.
Who Bears the Cost
- Selected VISNs and VA administrative staff: Even though treatment costs come from donated funds, VA must allocate personnel time and infrastructure to run the pilot, manage contracts, and ensure compliance with accreditation and reporting requirements.
- Medical facilities seeking to participate: Clinics that are not already accredited may face the expense and time of meeting accreditation standards or upgrading equipment to participate.
- Donors and philanthropic organizations: The program’s scale and continuity depend on donations, so funders shoulder the financial burden and attendant oversight or reporting expectations.
- Veterans outside the two VISNs: By concentrating the pilot geographically, the bill effectively shifts cost/access burdens to veterans living outside the participating VISNs who will not benefit from the pilot’s services.
Key Issues
The Core Tension
The central dilemma: expand access to a therapy many veterans request now, even where definitive evidence of long‑term benefit is lacking, or withhold broader availability until stronger, longer‑term evidence emerges—while designing a pilot that is both rapid and rigorous enough to inform future policy. The bill prioritizes immediate access through a donor-funded, time-limited program at the possible expense of generalizability, consistent oversight, and durable funding.
The bill creates practical and policy trade-offs. Relying exclusively on donated funds constrains program scale, creates uncertainty about how many veterans can enroll, and risks uneven geographic distribution tied to donor priorities.
Donor-funded models also raise governance questions: the statute allows the Secretary to spend donations for HBOT without fiscal-year limits but does not specify donor disclosure, conflicts-of-interest safeguards, or limits on donor influence over patient selection or site choice. Those omissions could complicate public oversight.
Methodologically, concentrating the pilot in two VISNs and limiting it to three years reduces statistical power and generalizability. A short, geographically narrow pilot may produce preliminary outcome signals but is unlikely to settle questions about long-term functional outcomes, durability of benefit, or subgroup responses.
The statutory allowance for investigational device exemptions gives VA flexibility to use non‑cleared devices under IDEs, but it also raises ethical and regulatory concerns about how informed consent, IDE monitoring, and adverse-event reporting will be handled when clinical care and device research overlap. Finally, the GAO update is due within one year—likely before the pilot has completed—so Congress will receive an evidence snapshot skewed toward preexisting trials rather than pilot-generated outcomes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.